Danish drugmaker Novo Nordisk has reduced the price of its popular weight-loss drug, Wegovy, by up to 37% from its launch price in India. This move is aimed at increasing its market share in the fast-growing Indian market for obesity treatments. The company's document sent to distributors shows the price...
Eli Lilly to Invest $1 Billion in India Manufacturing
Eli Lilly, announced an investment exceeding $1 billion to establish new contract manufacturing operations in India. Central to this initiative is the development of a major manufacturing and quality facility in Hyderabad, Telangana. This multi-year investment represents one of the most significant commitments by a global drug maker in India...
Eli Lilly Plans to Bring its Oral Weight-Loss Drug in India
Eli Lilly plans to introduce its weight-loss pill, orforglipron, in India, offering a non-injectable alternative that may appeal to patients wary of injections. Orforglipron belongs to the GLP-1 drug class, which curbs appetite and mirrors the mechanism of Lilly’s successful injectables Mounjaro and Zepbound. Though not yet approved anywhere globally,...
Eli Lilly Launches $180M Tech Hub in India to Drive Global Innovation
Indianapolis, Indiana-headquartered Eli Lilly inaugurated a new technology and innovation center in Hyderabad, India, marking an expansion of its global digital capabilities. The site will serve as a hub focused on artificial intelligence, automation, cloud computing, and software engineering. The Hyderabad center has already hired 100 professionals and plans to...
Eli Lilly Heats Up Weight-Loss Drug Race in India
Eli Lilly has launched its Mounjaro Kwikpen injector in India, intensifying competition with Novo Nordisk’s Wegovy. The Kwikpen, approved in June by India’s drug regulator, offers six dose strengths ranging from 2.5 mg to 15 mg. Prices for a month’s supply are: Dose (mg) Price (INR) Price (USD) 2.5 ₹14,000...
Eli Lilly’s Mounjaro Sees Strong Start in India
Eli Lilly's diabetes and weight-loss drug, Mounjaro, has received a "positive" response in India, with the company now focusing on meeting the significant demand in the world's most populous country. Lilly launched Mounjaro in India in March, ahead of competitor Novo Nordisk, tapping into a market grappling with increasing rates...